Table 2.
DNA-targeted therapies | Agents |
Akt modulation |
|||||||
All papers1 | Non-original2 | Relevant papers3 | PI3K/Akt inhibitors4 | ||||||
LY294002 | Wortmannin | BEZ235 | Perifosine | MK2206 | |||||
Platinum | Carboplatin | 68 | 6 | 51 | 3 | 1 | 0 | 0 | 4 |
Cisplatin | 631 | 15 | 589 | 85 | 22 | 8 | 9 | 5 | |
Oxaliplatin | 71 | 5 | 59 | 5 | 2 | 0 | 0 | 0 | |
Taxane | Docetaxel | 149 | 13 | 127 | 9 | 2 | 3 | 1 | 3 |
Paclitaxel | 363 | 18 | 331 | 47 | 15 | 4 | 2 | 5 | |
Antimetabolite | Fluorouracil | 191 | 5 | 174 | 18 | 6 | 0 | 2 | 3 |
Gemcitabine | 213 | 14 | 191 | 16 | 8 | 3 | 1 | 1 | |
Pemetrexed | 35 | 3 | 32 | 5 | 2 | 1 | 0 | 0 | |
Radiation | Irradiation/radiation | 1649 | 186 | 1356 | 151 | 82 | 12 | 13 | 5 |
Total articles | (9 agents) | 3370 | 265 | 2910 | 339 | 140 | 31 | 28 | 26 |
Terms used in the search: Query agent/radiation, and Akt, within whole the article with no language limitation, as of September, 2014;
Including the retracted publication, duplicate publication or non-original papers, including Review articles, Letters and Editorials, Comments, Case Reports, etc.;
Relevant with regard to the modulation of Akt by the query agent. [p-Akt OR pAkt OR "phospho-Akt" OR (phosphorylat* Akt) OR “Akt phosphorylation” OR “Akt inhibition” OR “Akt modulation” OR (inhibit* Akt) OR “inactivation of Akt” OR “Akt inactivation” OR “activation of Akt” OR “inactivating Akt”];
Suppressing Akt cascade by a PI3K/Akt inhibitor to sensitize the query agent. PI3K: Phosphatidylinositol 3 kinase.